Pharmacogenetics of Pain: The Future of Personalized Medicine

  • Lynn R. Webster


Physicians who treat chronic pain using opioids recognize that patients vary considerably in their responses to medications and painful stimuli. An increasing body of scientific literature supports the observation that the success or failure of opioid pharmacotherapy for pain may be rooted in individual genetic variations (Clin J Pain 26(Suppl 10):S16–S20, 2010; Curr Opin Anaesthesiol 20(5):478–484, 2007; Pain 109(3):488–496, 2004). Given the advances, genetic research appears to lay a foundation for future pain therapy informed by an appreciation of each person’s unique genome. In essence, applied pharmacogenetics – the intersection of pharmaceuticals and genetics – heralds personalized medicine. The genome determines a person’s potential response to a pain stimulus or analgesic; however, it is social and environmental experiences that will influence the final expression (Arthritis Res Ther 8(5):218, 2006). Environmental factors contribute to pain because pain is a multifactorial experience, largely influenced by affective input from anticipatory and emotional areas of the brain. The precise size of the contribution of genetics and environment to pain sensitivity is uncertain and is influenced by the type of pain stimulus (Pain 136(1–2):21–29, 2008). The field of pharmacogenetics is constantly evolving. The process of isolating candidate genes that contribute to such specific responses as pain sensitivity and speed of drug metabolism is painstaking. Studies also suggest that gender and ethnic differences in pain sensitivity have a genetic contribution, expressed through genetic determinations of cognitive, limbic, and affective neural networks (Pain 109(3):488–496, 2004). However, additional studies found ethnic variations in pain response to be insignificant when controlling for potentially confounding variables, including pain-coping mechanisms (Pain Med 6(1):88–98, 2005). Failure to replicate some findings underlines the difficulty of determining which genetic markers promise clinical utility. Even well-supported innovations and insights from the research laboratory do not yet translate to clinical practice in most instances. Patients who suffer from intractable pain and the physicians who treat them are still locked in a clinical environment where conventional treatments for chronic pain tend to work only for some patients and then sporadically and imperfectly. As advances in research continue and the cost of genome sequencing drops, the association between genetic profiles and pain profiles should grow clearer. The aim of this chapter is to provide the reader with an overview of the potential clinical implications of understanding the unique genetic pain processing of the individual and how pharmacogenetic therapy might inform personalized medical care.


Transient Receptor Potential Vanilloid Pain Sensitivity Migraine With Aura Pain Processing Opioid Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Dr. Webster acknowledges the contribution of medical writer Beth Dove of Lifetree Clinical Research and Pain Clinic, Salt Lake City, Utah, in the preparation of this manuscript.


  1. Akkuş, S., Delibaş, N., & Tamer, M. N. (2000). Do sex hormones play a role in fibromyalgia? Rheumatology (Oxford, England), 39(10), 1161–1163.CrossRefGoogle Scholar
  2. Aklillu, E., Persson, I., Bertilsson, L., et al. (1996). Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther, 278, 441–446.PubMedGoogle Scholar
  3. Argoff, C. E. (2010). Clinical implications of opioid pharmacogenetics. The Clinical Journal of Pain, 26(Suppl 10), S16–S20.PubMedCrossRefGoogle Scholar
  4. Belfer, I., Wu, T., Kingman, A., et al. (2004). Candidate gene studies of human pain mechanisms: methods for optimizing choice of polymorphisms and sample size. Anesthesiology, 100(6), 1562–1572.PubMedCrossRefGoogle Scholar
  5. Buskila, D., & Sarzi-Puttini, P. (2006). Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. Arthritis Research & Therapy, 8(5), 218.CrossRefGoogle Scholar
  6. Campbell, C. M., France, C. R., Robinson, M. E., Logan, H. L., Geffken, G. R., & Fillingim, R. B. (2008). Ethnic differences in diffuse noxious inhibitory controls. The Journal of Pain, 9(8), 759–766.PubMedCrossRefGoogle Scholar
  7. Cepeda, M. S., & Carr, D. B. (2003). Women experience more pain and require more morphine than men to achieve a similar degree of analgesia. Anesth Analg, 97(5), 1464–1468.PubMedCrossRefGoogle Scholar
  8. Chou, R., Fanciullo, G. J., Fine, P. G., American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel, et al. (2009). Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. The Journal of Pain, 10(2), 113–130.PubMedCrossRefGoogle Scholar
  9. Chou, W. Y., Wang, C. H., Liu, P. H., et al. (2006). Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology, 105(2), 334–337.PubMedCrossRefGoogle Scholar
  10. Chou, W. Y., Yang, L. C., Lu, H. F., et al. (2006). Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiologica Scandinavica, 50(7), 787–792.PubMedCrossRefGoogle Scholar
  11. Diatchenko, L., Slade, G. D., & Nackley, A. G. (2005). Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Human Molecular Genetics, 14(1), 135–143.PubMedCrossRefGoogle Scholar
  12. EGAPP Working Group Recommendations. CDC’s Office of Public Health Genomics, Evaluation of Genomic Applications in Practice and Prevention (EGAPP). Available at: Accessed October 6, 2010.
  13. Evans, W. E., Relling, M. V., Rahman, A., McLeod, H. L., Scott, E. P., & Lin, J. S. (1993). Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. The Journal of Clinical Investigation, 91(5), 2150–2154.PubMedCrossRefGoogle Scholar
  14. Fillingim, R. B., King, C. D., Ribeiro-Dasilva, M. C., Rahim-Williams, B., & Riley, J. L., III. (2009). Sex, gender, and pain: a review of recent clinical and experimental findings. The Journal of Pain, 10(5), 447–485. Review.PubMedCrossRefGoogle Scholar
  15. Fishbain, D. A., Fishbain, D., Lewis, J., et al. (2004). Genetic testing for enzymes of drug metabolism: does it have clinical utility for pain medicine at the present time? A structured review. Pain Medicine, 5, 81–93.PubMedCrossRefGoogle Scholar
  16. Gear, R. W., Miaskowski, C., Gordon, N. C., et al. (1996). Kappa-opioids produce significantly greater analgesia in women than in men. Nature Medicine, 2(11), 1248–1250.PubMedCrossRefGoogle Scholar
  17. GeneReviews. Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine; 2010. Available at: Accessed October 6, 2010.
  18. Genetic Testing Registry. Bethesda, MD: Office of Science Policy, National Library of Medicine; 2010. Available at: Accessed October 5, 2010.
  19. Hamburg, M. A., & Collins, F. S. (2010). The path to personalized medicine. The New England Journal of Medicine, 363(4), 301–304.PubMedCrossRefGoogle Scholar
  20. Holliday, K. L., Nicholl, B. I., Macfarlane, G. J., Thomson, W., Davies, K. A., & McBeth, J. (2009). Do genetic predictors of pain sensitivity associate with persistent widespread pain? Molecular Pain, 5, 56.PubMedCrossRefGoogle Scholar
  21. Ingelman-Sundberg, M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. The Pharmacogenomics Journal, 5(1), 6–13.PubMedCrossRefGoogle Scholar
  22. Kim, H., Neubert, J. K., San Miguel, A., et al. (2004). Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain, 109(3), 488–496.PubMedCrossRefGoogle Scholar
  23. Klepstad, P., Fladvad, T., Skorpen, F., On behalf of the European Palliative Care Research Collaborative (EPCRC) and the European Association for Palliative Care Research Network, et al. (2011). Influence from genetic variability on opioid use for cancer pain: A European genetic association study of 2294 cancer pain patients. Pain, 152(5), 1139–1145.PubMedCrossRefGoogle Scholar
  24. Lacroix-Fralish, M. L., Ledoux, J. B., & Mogil, J. S. (2007). The Pain Genes Database: An interactive web browser of pain-related transgenic knockout studies. Pain, 1–2, 3.e1–4.CrossRefGoogle Scholar
  25. Le Maitre, C. L., Freemont, A. J., & Hoyland, J. A. (2005). The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. Arthritis Research & Therapy, 7(4), R732–R745.CrossRefGoogle Scholar
  26. Le Maitre, C. L., Hoyland, J. A., & Freemont, A. J. (2007). Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: an in situ zymographic and gene therapy study. Arthritis Research & Therapy, 9(4), R83.CrossRefGoogle Scholar
  27. Martin, V. T. (2009). Ovarian hormones and pain response: a review of clinical and basic science studies. Gender Medicine, 6(Suppl 2), 168–192.PubMedCrossRefGoogle Scholar
  28. Mercadante, S., & Bruera, E. (2006). Opioid switching: a systematic and critical review. Cancer Treatment Reviews, 32, 304–315.PubMedCrossRefGoogle Scholar
  29. Miller G. Genetics of opioid prescribing: many questions, few answers. Pain Medicine News 2010 Feb; 8(02). Available at: Accessed September 29, 2010.
  30. Mobascher, A., Brinkmeyer, J., Thiele, H., et al. (2010). The val158met polymorphism of human catechol-O-methyltransferase (COMT) affects anterior cingulate cortex activation in response to painful laser stimulation. Molecular Pain, 6, 32.PubMedCrossRefGoogle Scholar
  31. Mogil, J. S., Wilson, S. G., Chesler, E. J., et al. (2003). The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proceedings of the National Academy of Sciences of the United States of America, 100(8), 4867–4872.PubMedCrossRefGoogle Scholar
  32. Nackley, A. G., Tan, K. S., Fecho, K., Flood, P., Diatchenko, L., & Maixner, W. (2007). Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. Pain, 128(3), 199–208.PubMedCrossRefGoogle Scholar
  33. Nicholl, B. I., Holliday, K. L., Macfarlane, G. J., European Male Ageing Study Group, et al. (2010). No evidence for a role of the catechol-O-methyltransferase pain sensitivity haplotypes in chronic widespread pain. Annals of the Rheumatic Diseases, 69(11), 2009–2012.PubMedCrossRefGoogle Scholar
  34. Nielsen, C. S., Stubhaug, A., Price, D. D., Vassend, O., Czajkowski, N., & Harris, J. R. (2008). Individual differences in pain sensitivity: genetic and environmental contributions. Pain, 136(1–2), 21–29.PubMedCrossRefGoogle Scholar
  35. Online Mendelian Inheritance in man (OMIM). Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine; 2010. Available at: Accessed October 6, 2010.
  36. Pasternak, G. W. (2001). Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends in Pharmacological Sciences, 22(2), 67–70. Review.PubMedCrossRefGoogle Scholar
  37. Reimann, F., Cox, J. J., Belfer, I., et al. (2010). Pain perception is altered by a nucleotide polymorphism in SCN9A. Proceedings of the National Academy of Sciences of the United States of America, 107(11), 5148–5153.PubMedCrossRefGoogle Scholar
  38. Ribeiro-Dasilva, M. C., Peres Line, S. R., Santos MC, Leme Godoy dos, Arthuri, M. T., Hou, W., Fillingim, R. B., et al. (2009). Estrogen receptor-alpha polymorphisms and predisposition to TMJ disorder. The Journal of Pain, 10(5), 527–533.PubMedCrossRefGoogle Scholar
  39. Ronald, G., Lafrenière, M. Zameel, Cader, Jean-François Poulin, et al. (2010). A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Nature Medicine, 16, 1157–1160.CrossRefGoogle Scholar
  40. Solovieva, S., Leino-Arjas, P., Saarela, J., Luoma, K., Raininko, R., & Riihimäki, H. (2004). Possible association of interleukin 1 gene locus polymorphisms with low back pain. Pain, 109(1–2), 8–19.PubMedCrossRefGoogle Scholar
  41. Stamer, U. M., & Stüber, F. (2007). Genetic factors in pain and its treatment. Current Opinion in Anaesthesiology, 20(5), 478–484.PubMedCrossRefGoogle Scholar
  42. Zhang, W., Chang, Y. Z., Kan, Q. C., et al. (2010). Association of human micro-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patients. Anaesthesia, 65(2), 130–135.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Lynn R. Webster
    • 1
    • 2
  1. 1.Lifetree Clinical ResearchSalt Lake CityUSA
  2. 2.American Academy of Pain MedicineGlenviewUSA

Personalised recommendations